Literature DB >> 14599635

Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review.

Rex T Wang1, Ronald L Koretz, Hal F Yee.   

Abstract

PURPOSE: To assess the evidence supporting the efficacy of weight reduction for patients with nonalcoholic fatty liver.
METHODS: Potentially relevant studies were identified by a computerized search of databases and a manual search of abstracts from scientific meetings. Studies were included if they reported histology, serum aminotransferase levels, or radiological imaging of the liver in obese adult patients who had undergone weight reduction. Weight reduction regimens included diet, exercise, antiobesity medications, gastric bypass, gastroplasty, or any combination of these interventions. Studies involving jejunoileal or small bowel bypass surgery were excluded.
RESULTS: We identified 517 potentially relevant studies, of which 15 met the inclusion criteria: one randomized controlled trial (in abstract form), two nonrandomized controlled trials, nine case series, one retrospective review, and two case reports. Three studies included more than 50 patients, whereas nine studies had 25 or fewer patients. Twelve studies used behavioral, dietary, or pharmacologic therapy for weight reduction, and three studies used surgical interventions. Although all 15 studies demonstrated overall improvement in the measurements of liver outcome after weight reduction, more than half did not report histologic results.
CONCLUSION: Despite general acceptance that weight reduction is an effective therapy for nonalcoholic fatty liver, this systematic review found little data to support or refute this recommendation.

Entities:  

Mesh:

Year:  2003        PMID: 14599635     DOI: 10.1016/s0002-9343(03)00449-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  37 in total

1.  Treatment options for nonalcoholic Fatty liver disease.

Authors:  Shivakumar Chitturi
Journal:  Therap Adv Gastroenterol       Date:  2008-11       Impact factor: 4.409

2.  Current status of therapy in nonalcoholic Fatty liver disease.

Authors:  Scott McNear; Stephen A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

Review 3.  Nonalcoholic fatty liver disease and HIV infection.

Authors:  Raphael B Merriman
Journal:  Curr HIV/AIDS Rep       Date:  2006-09       Impact factor: 5.071

4.  Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.

Authors:  Takamasa Ohki; Akihiro Isogawa; Nobuo Toda; Kazumi Tagawa
Journal:  Clin Drug Investig       Date:  2016-04       Impact factor: 2.859

Review 5.  Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment.

Authors:  Steven D Lidofsky
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

6.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

7.  Methionine deficiency and hepatic injury in a dietary steatohepatitis model.

Authors:  Helieh S Oz; Theresa S Chen; Manuela Neuman
Journal:  Dig Dis Sci       Date:  2007-08-21       Impact factor: 3.199

8.  Nonalcoholic fatty liver disease in Japanese patients with severe obesity who received laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) in comparison to non-Japanese patients.

Authors:  Satoru Kakizaki; Daichi Takizawa; Yuichi Yamazaki; Yuka Nakajima; Takeshi Ichikawa; Ken Sato; Hitoshi Takagi; Masatomo Mori; Kazunori Kasama
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

9.  Enhanced Steatosis and Fibrosis in Liver of Adult Offspring Exposed to Maternal High-Fat Diet.

Authors:  Michael D Thompson; Mary J Cismowski; Aaron J Trask; Scott W Lallier; Amanda E Graf; Lynette K Rogers; Pamela A Lucchesi; David R Brigstock
Journal:  Gene Expr       Date:  2016-06-23

10.  Association among C-reactive protein, Fatty liver disease, and cardiovascular risk.

Authors:  Javier Lizardi-Cervera; Norberto C Chavez-Tapia; Oliver Pérez-Bautista; Martha H Ramos; Misael Uribe
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.